<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00920413</url>
  </required_header>
  <id_info>
    <org_study_id>02-044</org_study_id>
    <nct_id>NCT00920413</nct_id>
  </id_info>
  <brief_title>Oral Vitamin C for Correction of Anemia in Patients Receiving Peritoneal Dialysis</brief_title>
  <official_title>Randomized, Double-Blind, Placebo-Controlled Trial of Oral Vitamin C on Correction of Anemia in Patients Receiving Peritoneal Dialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Unity Health Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Unity Health Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      People with kidney failure are at risk for the development of anemia. Anemia is a decrease in&#xD;
      the production of hemoglobin, a substance that carries oxygen in the blood. The majority of&#xD;
      patients require erythropoietin and iron supplementation to correct the anemia. In some&#xD;
      patients, the hemoglobin fails to rise to a desired level despite treatment with&#xD;
      erythropoietin and iron. There have been several studies in hemodialysis patients showing&#xD;
      that vitamin C given intravenously helps to correct anemia in patients already on&#xD;
      erythropoietin and iron.&#xD;
&#xD;
      The purpose of this study is to determine whether oral vitamin C will improve parameters of&#xD;
      anemia in patients receiving peritoneal dialysis.&#xD;
&#xD;
      Description of the research&#xD;
&#xD;
      This is a randomized, double blind, placebo controlled study. Participants will be randomized&#xD;
      in a 1:1 ratio to oral vitamin C 500mg once a day or placebo for 3 months. All participants&#xD;
      will be receiving oral iron supplementation, subcutaneous erythropoietin and a B and C&#xD;
      complex vitamin containing 100mg of vitamin C. Lab parameters (hemoglobin, TSAT, ferritin)&#xD;
      will be done at baseline and then monthly. The primary outcome is percent change from&#xD;
      baseline in transferrin saturation. Secondary objectives are percent change in ferritin,&#xD;
      hemoglobin and erythropoietin dose from baseline.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomized in a 1:1 ratio to Vitamin C 500mg orally once daily or matching&#xD;
      placebo for 3 months. Randomization codes will be kept by the Research Pharmacy and&#xD;
      investigators and patients will be blinded to treatment. Patients currently taking vitamin C&#xD;
      supplements (excluding the 100mg of vitamin C contained in a B and C complex vitamin, a&#xD;
      supplement used by all peritoneal dialysis patients), will be taken off the vitamin C and&#xD;
      then randomized to one of the treatment arms after a 1 month washout period. At the end of 3&#xD;
      months, the effects of vitamin C on the change in transferrin saturation from baseline will&#xD;
      be evaluated to identify which patients, if any, benefited from treatment. Hemoglobin, serum&#xD;
      iron, total iron binding capacity, ferritin, transferrin saturation and erythropoietin dose&#xD;
      will also be assessed. The dose and formulation of recombinant erythropoietin and oral iron&#xD;
      will be adjusted during the study period according to standard practice algorithms currently&#xD;
      used in the clinic. The addition of vitamin C does not pose any risk to the patients and will&#xD;
      be dispensed to the patient by the Research Pharmacy at St. Michael's Hospital free of&#xD;
      charge.&#xD;
&#xD;
      Patient population Inclusion criteria Receiving peritoneal dialysis for 2 months&#xD;
&#xD;
      Exclusion criteria Red blood cell folate &lt; 3.9 nmol/L Serum B12 &lt;110 pmol/L Bleeding, blood&#xD;
      transfusions, acute liver disease in the previous 3 months&#xD;
&#xD;
      Assessments Parathyroid hormone Baseline B12 Baseline Folate Baseline Hemoglobin Baseline and&#xD;
      monthly Hematocrit Baseline and monthly Ferritin Baseline and monthly Transferrin saturation&#xD;
      Baseline and monthly Serum iron Baseline and monthly&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2002</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>difference in percent change from baseline to 3 months in transferrin saturation between vitamin C and placebo</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>difference in percent change from baseline to 3 months in hemoglobin,ferritin and epoetin dose (each determined separately)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Anemia</condition>
  <condition>Peritoneal Dialysis</condition>
  <arm_group>
    <arm_group_label>vitamin C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>vitamin C 500mg orally once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin C</intervention_name>
    <description>vitamin C 500mg orally once a day</description>
    <arm_group_label>vitamin C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Receiving peritoneal dialysis for 2 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Red blood cell folate &lt; 3.9 nmol/L&#xD;
&#xD;
          -  Serum B12 &lt;110 pmol/L&#xD;
&#xD;
          -  Bleeding, blood transfusions, acute liver disease in the previous 3 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lori A MacCallum, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unity Health Toronto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <study_first_submitted>June 12, 2009</study_first_submitted>
  <study_first_submitted_qc>June 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2009</study_first_posted>
  <last_update_submitted>June 12, 2009</last_update_submitted>
  <last_update_submitted_qc>June 12, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 15, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr. Lori MacCallum</name_title>
    <organization>St. Michael's Hospital</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

